• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Novartis Stock Is Poised to Rise Another 15% From Here

The stock's performance has been impressive in the past three months.
By BRUCE KAMICH
Jan 08, 2019 | 10:11 AM EST
Stocks quotes in this article: NVS

In his first "Executive Decision" segment of Mad Money Monday night from the West Coast, our own Jim Cramer sat down with Dr. Vas Narasimhan, CEO of Novartis AG (NVS) . Novartis is one of the companies leading in innovation in medicines and cutting-edge drugs. Narasimhan said the company makes consistent investments into research and development every year. There are 26 drugs currently in the company's pipeline.

Innovation involves making long-term bets on completely new types of treatments, he added, which is why you're seeing Novartis moving into areas such as gene therapies that can offer patients cures instead of prolonged treatments. That's also why Novartis is spinning off its eye care business, Alcon, in order to focus on its drug pipeline which includes a drug for migraines. Novartis also has drugs on the horizon to treat arthritis and even heart failure. Targeted cancer treatments with all-new delivery techniques to ensure the latest drugs reach their intended destinations are also in the pipeline.

Sounds promising but let's take a look at the charts and indicators to round out the analysis.

In the daily bar chart of NVS, below, we can see an interesting pattern to the price movement the past 12 months. Prices declined from late January to late June and staged a recovery into early December. The price strength in October and November is interesting in that the broad market was weak and the level of trading volume for NVS was heavier than what was seen in prior months.

Prices outperformed on a relative basis and on strong volume -- a sign that investors moved money into NVS (and maybe out of things like technology). In December sellers of NVS became a little more aggressive and prices declined to retest the flat to slightly rising 200-day moving average line from above. NVS rebounded into the new year and is now only a few dollars below the declining 50-day moving average line.

The daily On-Balance-Volume (OBV) line shows an overall positive pattern, in my opinion. In the first half of 2018 when prices declined about $20 the OBV line only weakened slightly from April to June. From late June the OBV line has improved and the low in December is higher than the low in October. This may be a subtle improvement but I think it is bullish clue that many traders probably are missing.

In the bottom panel is the Moving Average Convergence Divergence (MACD) oscillator, which very recently crossed to the upside from below the zero line. This crossover is considered a cover shorts buy signal or a buy when the stock is still in a downtrend.

In the weekly bar chart of NVS, below, we can see a mostly positive alignment of the indicators. Even with the decline in December the prices of NVS are still above the rising 40-week moving average line.

The weekly OBV line made a low in June and has risen since suggesting several months of accumulation. The weekly MACD oscillator has been above the zero line since late August and is poised to turn up to a fresh outright go long signal in the weeks ahead.

In this Point and Figure chart of NVS, below, we can see an uptrend from late 2016 and we can see a downside price target or objective of $72.83. A new low for the move down at $81.44 would be bearish, should it happen and that may precipitate further losses but I doubt if prices will sink as low as the $72 area.

Bottom-line strategy: I am very impressed in how NVS has performed in the past three months. While the "sky was falling" for many extended technology names, NVS was a "rock." Traders and investors could probe the long side of NVS at current levels and on strength above the 50-day moving average line. Risk a close below $81 while looking for another leg higher. The $100 area is my price target.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Health Care Equipment & Services | Healthcare | Pharmaceuticals | Mad Money

More from Stocks

NeoGenomics Is Ready to Turn Higher

Bruce Kamich
Apr 16, 2021 9:15 AM EDT

Here's our technical strategy.

My Favorite Day of the Month: Options Expiration Day

Bret Jensen
Apr 16, 2021 9:04 AM EDT

I have become a huge devotee of this simple option strategy. Here are two recent examples from this week.

American Eagle Outfitters Has Bullish Charts but a Sell Stop Is a Good Idea

Bruce Kamich
Apr 16, 2021 8:28 AM EDT

Let's review the charts and indicators.

China's Economy, Retail Sales, Helicopter Money, Walmart's Autonomous Vehicles

Stephen Guilfoyle
Apr 16, 2021 8:09 AM EDT

The 'organic' economy has to take over at some point, and at that point, at least in theory, demand for credit should accelerate.

China's Economy Surges 18.3% as Communist Narrative Gets Back on Track

Alex Frew McMillan
Apr 16, 2021 7:54 AM EDT

China's national economy has had a 'good start,' according to the statistics bureau, posting unprecedented growth that brings it back to pre-pandemic levels.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:05 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How recency bias and the Pareto Principle impact y...
  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login